Get started
Author

Fathima Zumla Cader

Observed names: FZ Cader, Fathima Z. Cader, Zumla Cader
Observed institutions: AstraZeneca (United Kingdom), Brigham and Women's Hospital, Harvard University, Cancer Research UK, Birmingham Children's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, University of Birmingham
ORCID: 0000-0001-5107-0146
Observed ORCID: 0000-0001-5107-0146
OpenAlex ID: A5055960268
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
2018 · Margaretha G.M. Roemer, Robert A. Redd, et al. · Journal of Clinical Oncology · 364
PDF
EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors
2012 · Robert E. White, Patrick C. Rämer, et al. · Journal of Clinical Investigation · 166
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment
2018 · Fathima Zumla Cader, Ron C. J. Schackmann, et al. · Blood · 161
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion
2019 · Kirsty Wienand, Bjoern Chapuy, et al. · Blood Advances · 159
PDF
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
2020 · Fathima Zumla Cader, Xihao Hu, et al. · Nature Medicine · 142
The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1
2013 · Fathima Zumla Cader, Martina Vockerodt, et al. · Blood · 94
The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas
2010 · Fathima Zumla Cader, Pamela Kearns, et al. · Cancer Treatment Reviews · 42
Epstein-Barr virus and the origin of Hodgkin lymphoma
2014 · Martina Vockerodt, Fathima Zumla Cader, et al. · 癌症：英文版 · 41
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma
2024 · Julia Paczkowska, Ming Tang, et al. · Nature Communications · 18
PDF
Epstein–Barr virus, the germinal centre and the development of Hodgkin’s lymphoma
2014 · Ghada Mohamed, Katerina Vrzalikova, et al. · Journal of General Virology · 15
NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies
2021 · Marina Konopleva, Nitin Jain, et al. · Blood · 6
A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients with Classical Hodgkin Lymphoma
2020 · FZ Cader, X Hu, et al. · immuneACCESS · 6
Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial
2023 · Shukaib Arslan, Giovanni Marconi, et al. · Blood · 5
Hemophagocytic Lymphohistiocytosis Associated With 2 Cases of Pediatric Lymphocyte-depleted Classic Hodgkin Lymphoma
2019 · Fathima Z. Cader, Isabel Colmenero, et al. · Journal of Pediatric Hematology/Oncology · 3
Single-Cell RNA Sequencing Reveals the Interplay between Circulating CD4 + T Cells, B Cells and Cancer-Associated Monocytes in Classic Hodgkin Lymphoma Treated with PD-1 Blockade
2023 · Julia Paczkowska, Ming Tang, et al. · Blood · 2
Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion
2018 · Kirsty Wienand, Bjoern Chapuy, et al. · Blood · 2
Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
2022 · Shukaib Arslan, Shaun Fleming, et al. · Blood · 1
Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade
2019 · Kirsty Wienand, Bjoern Chapuy, et al. · Blood · 1
Abstract CT146: AZD0466 in patients with advanced non-Hodgkin lymphoma: Efficacy and safety in an open-label phase 1 trial
2024 · Geoffrey Chong, Franck Morschhauser, et al. · Cancer Research
P537: Safety and Tolerability of Azd0466 as Monotherapy for Patients With Advanced Hematological Malignancies - Preliminary Results From an Ongoing Phase I/ii Trial
2023 · Giovanni Marconi, Shukaib Arslan, et al. · HemaSphere
Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models
2023 · Courtney L. Andersen, Giulia Fabbri, et al. · Cancer Research
T028: Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
2022 · Julia Paczkowska, Ming Tang, et al. · HemaSphere
Abstract 5675: Single-cell mass cytometry of classical Hodgkin lymphoma defines an exhausted and immunosuppressive microenvironment
2018 · Fathima Z. Cader, Ron C. Schackmann, et al. · Cancer Research
The EBV Oncogene LMP1 Protects Lymphoma Cells From Cell Death Through The Collagen-Mediated Activation Of Discoidin Domain Receptor 1
2013 · Fathima Zumla Cader, Martina Vockerodt, et al. · Blood
An investigation of the aberrant expression and activation of receptor tyrosine kinases in hodgkin’s lymphoma
2011 · Fathima Zumla Cader · University of Birmingham Institutional Research Archive (University of Birmingham)
PDF
Works count: 25
Citation count: 1,228
H-index: 10
I10-index: 10
Year
Topic
Type